KAIROS DISCOVERY

Driven by Science. Focused on Impact.

New Strategies. Greater Precision. Real Impact.
We are building the next generation of targeted therapies to overcome the limitations of conventional kinase inhibition - and unlock new possibilities in cancer treatment.
Contact us
Cultivating relations with the strong and committed partners.
OUR MISSION

Targeted therapies for patients with cancers

At Kairos Discovery, we focus our efforts on developing innovative cancer therapies by targeting a class of proteins known as kinases. 



While kinase inhibitors have transformed cancer care, many remain limited by off-target toxicity, acquired resistance, and the inability to modulate non-catalytic or "undruggable" kinase functions.



Our pipeline focuses on next-generation modalities - including a bivalent CK2α inhibitor and a CDK-targeted protein degrader - designed to overcome these limitations and unlock new opportunities in oncology.
Discover our Pipeline

+

1

years
Our main asset - a bivalent CK2ɑ inhibitor - is built upon over a decade of cutting-edge academic research, now translated into a drug discovery program.

+€

0.1

M

raised since company incorporation in October 2022, from committed investors and non-dilutive grants supporting our scientific vision.
OUR TEAM

A dedicated and complementary team

Kairos Discovery is led by a committed team combining deep scientific expertise, translational insight, and entrepreneurial drive.


Our core team is supported by experienced scientists, strategic advisors, and specialized consultants - all aligned to accelerate the development of our next-generation cancer therapies.


Together, we bring the focus, agility, and rigor needed to turn scientific innovation into therapeutic reality.
Meet our Team